FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2576108875> ?p ?o ?g. }

• W2576108875 endingPage "13791" @default.
• W2576108875 startingPage "13782" @default.
• W2576108875 abstract "// Jung Yong Hong 1 , Kyung Ju Ryu 2 , Chaehwa Park 3 , Mineui Hong 4 , Young Hyeh Ko 5 , Won Seog Kim 6 , Seok Jin Kim 2, 6 1 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea 2 Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea 3 Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 4 Department of Pathology, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Seoul, Korea 5 Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 6 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Correspondence to: Seok Jin Kim, email: kstwoh@skku.edu Keywords: survivin, epstein-barr virus, diffuse large B-cell lymphoma Received: May 14, 2016      Accepted: January 03, 2017      Published: January 13, 2017 ABSTRACT Survivin is an inhibitor of apoptosis and is upregulated by Epstein–Barr virus (EBV) latent genes. Given the frequent association of EBV with lymphoid malignancies, survivin is expected to have prognostic value in diffuse large B-cell lymphoma (DLBCL). Thus, we measured the pretreatment serum level of survivin in DLBCL patients and analyzed its association with survival outcome and EBV status, as represented by EBV-encoded RNA (EBER) in DLBCL. Pretreatment serum survivin level was measured in patients registered in a prospective cohort study ( n = 210), and serum survivin-positivity was defined as any detectable level of survivin. EBV status was determined using EBER in situ hybridization, and EBER-positivity was defined as 20% of examined cells showing nuclear positivity. Mean serum survivin level was higher in patients with relapsed or refractory disease than with responsive disease (59.89 pg/mL versus 17.34 pg/mL, P = 0.041). Serum survivin-positive patients had worse overall and progression-free survival ( P = 0.023 and 0.022, respectively). Serum survivin positivity was associated with unfavorable characteristics including stage. In patients with non-germinal center B-cell type DLBCL, serum survivin-positive patients also had significantly worse survival than serum survivin-negative patients ( P < 0.001). EBER-positivity was found in 6.7% (14/210) of patients, and EBER-positive patients had worse survival ( P < 0.05). Patients having concomitant positivity for serum survivin and EBER expression (2.8%, 6/210) showed extremely poor prognosis. In the present era of rituximab in DLBCL, DLBCL with serum survivin positivity showed adverse clinical features and followed worse clinical course, especially in non-GCB subtype DLBCL. EBER-positivity was still associated with worse outcomes in DLBCL." @default.
• W2576108875 created "2017-01-26" @default.
• W2576108875 creator A5000845948 @default.
• W2576108875 creator A5004166441 @default.
• W2576108875 creator A5013311116 @default.
• W2576108875 creator A5025270564 @default.
• W2576108875 creator A5035186338 @default.
• W2576108875 creator A5038504707 @default.
• W2576108875 creator A5071885891 @default.
• W2576108875 date "2017-01-13" @default.
• W2576108875 modified "2023-09-22" @default.
• W2576108875 title "Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP" @default.
• W2576108875 cites W1523461418 @default.
• W2576108875 cites W1540060031 @default.
• W2576108875 cites W1585598556 @default.
• W2576108875 cites W1992960292 @default.
• W2576108875 cites W1996279342 @default.
• W2576108875 cites W1999365649 @default.
• W2576108875 cites W2008901435 @default.
• W2576108875 cites W2010726668 @default.
• W2576108875 cites W2014485235 @default.
• W2576108875 cites W2034601852 @default.
• W2576108875 cites W2035523654 @default.
• W2576108875 cites W2037249620 @default.
• W2576108875 cites W2037796411 @default.
• W2576108875 cites W2045429389 @default.
• W2576108875 cites W2057239580 @default.
• W2576108875 cites W2058015212 @default.
• W2576108875 cites W2087681835 @default.
• W2576108875 cites W2090977926 @default.
• W2576108875 cites W2091999226 @default.
• W2576108875 cites W2102874235 @default.
• W2576108875 cites W2115795968 @default.
• W2576108875 cites W2137807267 @default.
• W2576108875 cites W2143705626 @default.
• W2576108875 cites W2144884472 @default.
• W2576108875 cites W2147246240 @default.
• W2576108875 cites W2150673622 @default.
• W2576108875 cites W2158267770 @default.
• W2576108875 cites W2161959295 @default.
• W2576108875 cites W2167119070 @default.
• W2576108875 cites W2170090299 @default.
• W2576108875 cites W2172003817 @default.
• W2576108875 cites W2172124462 @default.
• W2576108875 cites W2315021163 @default.
• W2576108875 cites W2398603241 @default.
• W2576108875 doi "https://doi.org/10.18632/oncotarget.14636" @default.
• W2576108875 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5355138" @default.
• W2576108875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28099151" @default.
• W2576108875 hasPublicationYear "2017" @default.
• W2576108875 type Work @default.
• W2576108875 sameAs 2576108875 @default.
• W2576108875 citedByCount "16" @default.
• W2576108875 countsByYear W25761088752017 @default.
• W2576108875 countsByYear W25761088752018 @default.
• W2576108875 countsByYear W25761088752020 @default.
• W2576108875 countsByYear W25761088752021 @default.
• W2576108875 countsByYear W25761088752022 @default.
• W2576108875 countsByYear W25761088752023 @default.
• W2576108875 crossrefType "journal-article" @default.
• W2576108875 hasAuthorship W2576108875A5000845948 @default.
• W2576108875 hasAuthorship W2576108875A5004166441 @default.
• W2576108875 hasAuthorship W2576108875A5013311116 @default.
• W2576108875 hasAuthorship W2576108875A5025270564 @default.
• W2576108875 hasAuthorship W2576108875A5035186338 @default.
• W2576108875 hasAuthorship W2576108875A5038504707 @default.
• W2576108875 hasAuthorship W2576108875A5071885891 @default.
• W2576108875 hasBestOaLocation W25761088751 @default.
• W2576108875 hasConcept C121608353 @default.
• W2576108875 hasConcept C126322002 @default.
• W2576108875 hasConcept C143998085 @default.
• W2576108875 hasConcept C2775975398 @default.
• W2576108875 hasConcept C2778559949 @default.
• W2576108875 hasConcept C2779338263 @default.
• W2576108875 hasConcept C502942594 @default.
• W2576108875 hasConcept C71924100 @default.
• W2576108875 hasConceptScore W2576108875C121608353 @default.
• W2576108875 hasConceptScore W2576108875C126322002 @default.
• W2576108875 hasConceptScore W2576108875C143998085 @default.
• W2576108875 hasConceptScore W2576108875C2775975398 @default.
• W2576108875 hasConceptScore W2576108875C2778559949 @default.
• W2576108875 hasConceptScore W2576108875C2779338263 @default.
• W2576108875 hasConceptScore W2576108875C502942594 @default.
• W2576108875 hasConceptScore W2576108875C71924100 @default.
• W2576108875 hasIssue "8" @default.
• W2576108875 hasLocation W25761088751 @default.
• W2576108875 hasLocation W25761088752 @default.
• W2576108875 hasLocation W25761088753 @default.
• W2576108875 hasLocation W25761088754 @default.
• W2576108875 hasOpenAccess W2576108875 @default.
• W2576108875 hasPrimaryLocation W25761088751 @default.
• W2576108875 hasRelatedWork W1563073167 @default.
• W2576108875 hasRelatedWork W2067304395 @default.
• W2576108875 hasRelatedWork W2091006759 @default.
• W2576108875 hasRelatedWork W2365747097 @default.
• W2576108875 hasRelatedWork W3001698141 @default.
• W2576108875 hasRelatedWork W3008207576 @default.
• W2576108875 hasRelatedWork W3032381670 @default.

• next